|
Getting your Trinity Audio player ready...
|
Advent International has agreed to sell Prague-based generic pharmaceutical company Zentiva to U.S. private equity firm GTCR for €4.1 billion ($4.8 billion), making it the largest private equity healthcare exit in Europe this year.
The transaction follows a competitive bidding process and significantly boosts the region’s healthcare exit value for 2025 to €23.7 billion—already exceeding the total recorded in 2024.
Zentiva, a leading producer of affordable medicines across Europe, has been under Advent’s ownership since 2018. The sale reflects continued investor interest in scalable healthcare assets and underscores the sector’s resilience amid broader market volatility.
